The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity
Open accessAbstract
Robust CD8+ T cell memory is essential for long-term protective immunity but is often compromised in cancer, where T cell exhaustion leads to loss of memory precursors. Immunotherapy via checkpoint blockade may not effectively reverse this defect, potentially underlying disease relapse. Here we report that mice with a CD8+ T cell-restricted neuropilin-1 (NRP1) deletion exhibited substantially enhanced protection from tumor rechallenge and sensitivity to anti-PD1 immunotherapy, despite unchanged primary tumor growth. Mechanistically, NRP1 cell-intrinsically limited the self-renewal of the CD44+PD1+TCF1+TIM3- progenitor exhausted T cells, which was associated with their reduced ability to induce c-Jun/AP-1 expression on T cell receptor restimulation, a mechanism that may contribute to terminal T cell exhaustion at the cost of memory differentiation in wild-type tumor-bearing hosts. These data indicate that blockade of NRP1, a unique 'immune memory checkpoint', may promote the development of long-lived tumor-specific T mem that are essential for durable antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the C-terminal motif of the cleaved S1 subunit can bind to neuropillin-1 (NRP-1),67,68 which negatively influences T cell memory.69”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Smyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
Self-citationCre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus
Srinivas, S., Watanabe, T., Lin, C.-S., William, C. M., Tanabe, Y., Jessell, T. M., & Costantini, F. (2001) · BMC Developmental Biology · doi:10.1186/1471-213x-1-4 · Cited by 3,121
Smart-seq2 for sensitive full-length transcriptome profiling in single cells
Picelli, S., Björklund, Å. K., Faridani, O. R., Sagasser, S., Winberg, G., & Sandberg, R. (2013) · Nature Methods · doi:10.1038/nmeth.2639 · Cited by 2,358
Cited by
Sorted by citations
Items 101–151 of 151
Ding, Y., Wang, Z., Chen, C., Wang, C., Li, D., & Qin, Y. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1091733 · Cited by 4
Zhao, Z., Wang, J., Liu, M., Li, Z., Cao, F., Xu, P., Fang, Q., Yang, J., Hu, Z., Wu, D., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13784-y · Cited by 3
Chu, C., Lu, B., Fu, W., Li, M., Dong, K., Lyu, D., Yao, Y., Li, Y., Liu, Y., Pan, X., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01806-9 · Cited by 3
Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis
Zhai, Y., Wang, Q., Nong, Q., Gao, M.-Y., Zhang, Y., Xiao, Q.-W., Tian, Y., Zhang, Z., Xu, F., & Zhang, P. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117183 · Cited by 4
Wang, Z., Lai, L., Ran, S., Li, Y., Zhao, J., Wu, J., Guo, C., Cui, J., & Xia, J. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07383-5 · Cited by 4
Zhang, B., Liu, Q., Li, L., Ye, Y., Guo, X., Xu, W., Chen, L., Mo, X., Nian, S., & Yuan, Q. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03893-1 · Cited by 3
Systematic pan‐cancer analysis identified neuropilin 1 as an immunological and prognostic biomarker
Ma, X., Zhao, Y., Shi, C.-C., Jiang, H., Liu, H.-N., Wang, H., Qin, X.-B., Wang, Y., & Han, Z.-X. (2023) · Cell Biochemistry and Function · doi:10.1002/cbf.3821 · Cited by 3
Abberger, H., Hose, M., Ninnemann, A., Menne, C., Eilbrecht, M., Lang, K. S., Matuschewski, K., Geffers, R., Herz, J., Buer, J., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011837 · Cited by 3
NRP1 downregulation correlates with enhanced ILC2 responses during IL ‐33 challenge
Wang, Y., Liu, G., Wang, J., Zhou, P., Zhang, L., Liu, Q., & Zhou, J. (2024) · Immunology · doi:10.1111/imm.13769 · Cited by 3
Hohlstein, P., Schumacher, E., Jhaisha, S. A., Adams, J. K., Pollmanns, M. R., Schneider, C. V., Hamesch, K., Horvathova, K., Wirtz, T. H., Tacke, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105438 · Cited by 4
Peng, H., Chen, Q., Ye, L., & Wang, W. (2025) · Biomedicines · doi:10.3390/biomedicines13040894 · Cited by 4
NRP1 and Furin as Putative Mediators of SARS-CoV-2 Entry into Human Brain Cells
Kumar, A., Narayan, R. K., Kumar, S., Pareek, V., Kumari, C., Jha, R. K., & Prasoon, P. (2022) · Re GEN Open · doi:10.1089/regen.2022.0047 · Cited by 3
Hu, J., Hu, W., & Yang, Y. (2022) · Journal of Oncology · doi:10.1155/2022/4965167 · Cited by 2
Wedel, J., Kochupurakkal, N. M., Kong, S. W., Bose, S., Lee, J.-W., Maslyar, M., Alsairafi, B., MacLeod, K., Liu, K., Zhang, H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci172218 · Cited by 2
DNA G-Quadruplex in NRP1 Promoter Facilitates SARS-CoV-2 Infection
Gong, P., Zhang, R., Xiao, K., Shu, H., Li, X., Fan, H., & Sun, X. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084422 · Cited by 1
Liu, F., Qin, Y., Luo, W., Ruan, X., Lu, L., Feng, B., & Yu, J. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1530334 · Cited by 1
Significance of a Novel Angiogenesis-Related Biomarker Neuropilin-1 in Keloids.
Jin, M., Lin, X.-Y., Wang, Y., Li, Y., Zhang, T., Zhuang, Z.-M., Zhong, X.-C., & Tan, W.-Q. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01481-x · Cited by 2
Dhamdhere, M. R., Gowda, C. P., Kawasawa, Y. I., Wang, H., Schell, T. D., & Spiegelman, V. S. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2584408 · Cited by 1
Zou, L., Chen, J., Bai, X., Wang, Y., Lu, C., Qiaoli, W., Tuerhong, S., Li, M., Zheng, Q., Meng, F., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1693755 · Cited by 1
Targeting intratumoral regulatory T cells by CD137 aptamer-shRNA chimeras
Lee, K. Y., Mei, Y., Liu, H., & Schwarz, H. (2025) · Immunotherapy Advances · doi:10.1093/immadv/ltaf037 · Cited by 1
Rainwater, R. R., Azevedo‐Pouly, A. C. P., Waldrip, Z. J., Hicks, B. H., Callais, N. A., Koss, B. S., Storey, A. J., Burdine, L. J., & Burdine, M. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116796 · Cited by 1
Weng, H., Ting, H.-K., Wang, H.-H., Peng, T.-J., Tang, S.-J., & Sun, K.-H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07943-3 · Cited by 1
Deng, Z., Zhang, C., Wei, H., Hu, Z., Hua, G., Li, Z., Wu, J., He, T., Wang, Y., CAI, Y., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-3669 · Cited by 1
Yee, S., Seon, J.-E., Seo, J.-E., Seo, H.-J., Seo, J.-H., Moon, S.-H., Koo, H.-S., Choi, H.-R., Kim, S., & Kang, H. (2026) · iScience · doi:10.1016/j.isci.2026.115505 · Cited by 1
Bariana, M., Anand, S. R., Batistick, M., Cassella, E., Anuncio, S. A., Aptekmann, A. A., Siegel, D. S. D., Oelke, M., Kim, S., Wang, R., et al. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100002 · Cited by 1
Snyder, A. J., Shasha, C., Ho, T., Garrison, S. M., Wilhelm, A. R., Kluesner, M. G., Ortiz, S., Nutt, W. S., Bingham, E., Bhise, S. S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648245 · Cited by 1
Vignali, D. (2022) · Journal of Interferon and Cytokine Research · doi:10.1089/jir.2021.29033.dav
Self-citationComprehensive Analysis of Novel Immune Checkpoint NeuropilinsPreprint
Bai, X., He, L., Zhang, X., Lao, M., Xu, J. G., Yang, H., & Liang, T. (2022) · Research Square · doi:10.21203/rs.3.rs-1601245/v1
Morianos, I., Tsitsopoulou, A., Potaris, Κ., Valakos, D., Fari, O., Vatsellas, G., Bostantzoglou, C., Photiades, A., Gaga, M., Xanthou, G., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-695724/v1
HDAC7 controls anti-viral and anti-tumor immunity by CD8 + T cellsPreprint
Yerinde, C., Keye, J., Durlanik, S., Freise, I., Nowak, F., Hsiao, H.-J., Letizia, M., Schlickeiser, S., Obermayer, B., Huck, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.18.508452
Kirchmair, A., Nemati, N., Lamberti, G., Trefny, M. P., Krogsdam, A., Siller, A., Hörtnagl, P., Schumacher, P., Sopper, S., Sandbichler, A. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.18.541159
Therapeutic effect of fully human anti-Nrp-1 antibody in non–small cell lung cancerPreprint
Zhang, B., Liu, Q., Li, L., Hu, Z., Guo, X., Ye, Y., Xu, W., Liao, X., Nian, S., & Yuan, Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3498692/v1
Immunomodulation by allograft endothelial cells
Bose, S., Do, V., Testini, C., Jadhav, S. S., Sailliet, N., Kho, A. T., Komatsu, M., Boneschansker, L., Kong, S. W., Wedel, J., et al. (2025) · Frontiers in Transplantation · doi:10.3389/frtra.2025.1518772
DNA-PKcs governs LAT-dependent signaling in CD4 + and CD8 + T cellsPreprint
Rainwater, R. R., Azevedo‐Pouly, A. C. P., Waldrip, Z. J., Hicks, B. H., Callais, N. A., Koss, B. S., Storey, A. J., Burdine, L. J., & Burdine, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.06.641745
Sun, C., Xu, M., Yan, M., Shen, M., Han, X., Zhang, H., Hu, C., Wang, Y., Wang, W., Jin, A., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103517
Zhang, Q., Pan, G., Wang, T., & Hao, J. (2025) · Archives of Medical Science · doi:10.5114/aoms/203010
Trujillo‐Ocampo, A., Borges, P., Grefe, M., de Freitas, M. V., Lee, S., Yuan, Q., Clinton, J., Li, D., He, H., Yu, L., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5362268
Tang, Y., Zhang, Q., Yuan, Z., Yin, D., Zhang, S., Sun, Y., Mo, C., Tang, Z., Zhao, J., & Tang, Y. (2025) · Cell Cycle · doi:10.1080/15384101.2025.2539645
Xing, K.-Y., Li, L.-S., Ma, Y.-N., & Zhu, J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47080652
Neuropilin-1 expression by solid tumors impairs CAR T cell functionPreprint
Condon, L., Bouillié, M., Fuentealba, J. R., Saitakis, M., & Hermine, O. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.16.676545
Zhao, C., Zhang, C., Zhang, X., Du, C., Liu, W., Zhou, Q., Dong, J., Yang, F., Dang, Y., Yang, A., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-04316-y
Morianos, I., Tsitsopoulou, A., Potaris, Κ., Valakos, D., Fari, O., Vatsellas, G., Bostantzoglou, C., Photiades, A., Gaga, M., Xanthou, G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16655802
Semaphorins: from CD8⁺ T cells to cancer immunotherapy
Liu, Z., Wu, Y., Xu, P., Xu, H., Yin, K., & Wang, S. (2026) · Biomarker Research · doi:10.1186/s40364-026-00903-5 · Cited by 1
Zheng, Y., Du, Y., Ma, Z., Luo, Y., Lu, J., & Shang, P. (2026) · Cancers · doi:10.3390/cancers18050768
Xiao, S., Allen, H. N., Babyok, O. L., Loya‐López, S., Fulton, S. A., Nelson, T. S., Khanna, R., & Saloman, J. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.06.723195
HDAC7 controls anti-viral and anti-tumor immunity by CD8+ T cells
Yerinde, C., Keye, J., Hsiao, H.-J., Durlanik, S., Freise, I., Nowak, F., Letizia, M., Schlickeiser, S., Obermayer, B., Huck, A., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1816695
Wang, J.-Y., Lan, C., Xia, Z., Cui, D., Lv, H., Qiang, N., Chen, G.-P., & Ao, J.-J. (2026) · Immunobiology · doi:10.1016/j.imbio.2026.153206
Rewriting CAR-T cell fate: CRISPR/Cas gene editing for solid tumor therapy
Liu, W., Gu, J., Xie, C., Bing, D., Liu, M., & Zhang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1910092
Aggarwal, V., Sun, Y., Liu, C., Cui, J., Manne, S., Dou, Y., Chen, Q., Brunazzi, E. A., Vignali, K. M., Wang, H., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241968
Self-citationXiang, Y., Su, P., Zhang, R., Zhao, D., Li, Z., Yang, W., 雷长城, Chen, H., Zhang, J., & Xiong, W. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1926600
He, R., Liu, Z., Meng, Q., Wu, K., Wu, J., Li, Y., Luo, O. J., & Li, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924940
Metadata
- Authors
- Liu, C., Somasundaram, A., Manne, S., Gocher, A. M., Szymczak-Workman, A. L., Vignali, K. M., Scott, E. N., Normolle, D. P., John Wherry, E., Lipson, E. J., Ferris, R. L., Bruno, T. C., Workman, C. J., & Vignali, D. A. A.
- Affiliations
- University of Pittsburgh (US)
- University of Pennsylvania (US)
- UPMC Hillman Cancer Center (US)
- Johns Hopkins University (US)
- Corresponding author
- Vignali, Dario A. A.
- ORCID
- Venue
- Nature Immunology
- Published
- 2020-07-13
- Volume
- 21
- Issue
- 9
- Pages
- 1010-1021
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- PMC
- PMC7442600
- OpenAlex
- W3040823189
- Cited by
- 151
- References
- 56
- Citations by year
- 2026: 13 · 2025: 36 · 2024: 18 · 2023: 27 · 2022: 31 · 2021: 20 · 2020: 6
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Health & Human Services | National Institutes of Health (CA203689, AI108545, CA082084, CA247004-01, AI117950, AI082630, AI112521, AI115712, CA210944)
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA047904, CA006973, CA097190)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- neuropilin-1, T cell exhaustion, CD8+ T cell memory, immune checkpoint, antitumor immunity, anti-PD-1 therapy, tumor rechallenge, T cell self-renewal
- MeSH terms
- Immune Checkpoint Proteins, Animals, Humans, Immune Tolerance, Immunity, Immunologic Memory, Melanoma, Experimental, Signal Transduction, Mice, Knockout, CD8-Positive T-Lymphocytes, Neuropilin-1, Cell Line, Tumor, Mice, Precursor Cells, T-Lymphoid, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
